Biomea Fusion BMF-650 (GLP-131) Phase I Topline Results Conference Call - BIOMEA FUSION INC

Financial Performance:

• Biomea Fusion is a cash-dependent biotech company not yet generating commercial revenue; financial focus is on capital allocation for R&D.
• No specific revenue, earnings, debt, or cash flow metrics were disclosed for the quarter, as the company remains in pre-revenue clinical stages.
• Management explicitly stated they do not envisage independently funding a large global clinical obesity program, seeking strategic partnerships to advance BMF650.

Guidance and Future Outlook:

• Plans to complete sub-chronic toxicology studies (13-week duration in rats and cynomolgus monkeys) before initiating Phase 2.
• intends to conduct a Phase 1b Cohort 6 (non-confined setting) to validate weight loss vs. placebo in a real-world eating environment.
• Potential for Phase 2 design to involve no titration (starting directly at 400 mg) if tolerability is confirmed.
• Expectations for ICOVA-MENI (the company's other core asset): Initiate two Phase 2 studies in Type 1 diabetes within the next two quarters, with 6-month response data in 18 months.
• Upcoming Phase 2 readouts for ICOVA-MENI expected in H1 next year (insulin-deficient patients) and H2 next year (combination with GLP-1s).
• Goal to secure FDA End-of-Phase 2 meetings for ICOVA-MENI and move toward late-stage development.

Business Segments and Product Lines:

• BMF650 (Oral GLP-1 Receptor Agonist):
  • Phase 1b results show mean weight reduction of 1.5% to 3.3% over 28 days in non-confined cohorts.
  • Cohort 5 (confined, one-step titration) showed 6.1% mean weight reduction (1.55 kg/week) at the 400 mg dose with no attenuation.
  • Designed with 26-fold lower receptor potency than oral foroglipron to separate weight loss from acute GI activation.
  • Achieved target systemic exposure (AUC ~79,000 ng·h/mL) with a low peak-to-trough ratio (1.7), supporting once-daily dosing.
• ICOVA-MENI (IKK2β Inhibitor):
  • Remains the core value driver; focus on Type 1 and Type 2 diabetes, including combination studies with semaglutide to preserve muscle and bone mass.

Market and Competitive Landscape:

• Addresses a major industry challenge: 65% of patients discontinue oral GLP-1 therapies within the first year due to GI tolerability issues.
• Differentiation strategy focuses on "persistence" and tolerability rather than maximizing acute weight loss percentages.
• Comparison to competitors (e.g., foroglipron, Curiva) indicates BMF650 offers a better safety profile and potentially simpler titration (one step vs. multiple).
• Market potential identified in licensing partners with failed oral GLP-1 programs or those seeking to enter the space with a distinct tolerability profile.

Risks and Challenges:

• Compliance: Cohort 4 showed unexpected weight gain in week one; post-hoc analysis suggests potential non-compliance (missed doses) rather than lack of efficacy.
• Confinement Data Interpretation: Cohort 5 was conducted in confinement where one of two placebo participants consumed only 33% of provided calories, complicating placebo-adjusted weight loss calculations.
• Toxicology Timeline: Phase 2 initiation is contingent on completing sub-chronic tox studies (13 weeks) in two species.
• Clinical Dilution: Risk of data noise due to small cohort sizes (8 participants per active arm) in Phase 1.

Management Commentary and Tone:

• Tone is cautiously optimistic and scientifically rigorous, emphasizing the separation of efficacy from GI side effects as the primary value proposition.
• Management expressed confidence in the "blowtorch vs. radiator" design hypothesis, noting that the 400 mg dose was tolerable with a single titration step.
• Strategic shift emphasized: avoiding capital-intensive independent global trials in favor of partnership/licensing to maximize strategic value while focusing resources on ICOVA-MENI.
• Confirmed interest in initiating a new Phase 1 cohort (Cohort 6) potentially with a partner to de-risk Phase 2.

Analyst Questions and Answers:

• Dose Selection: Management confirmed 400 mg is the target dose for Phase 2; higher doses (e.g., 600 mg) are not currently pursued to avoid excessive short-term weight loss that may not be sustainable or necessary.
• Differentiation: Key differentiator identified is tolerability allowing for faster titration or no titration, addressing the "persistence" gap in the current oral GLP-1 market.
• Animal-to-Human Translation: Monkey weight loss data (~12-15%) was explained to translate to human data (~5-6%) via metabolic scaling factors (approx. 3x), aligning with observed human results.
• Cardiovascular Safety: Mean heart rate increased by ~6.4 bpm, but no adverse events occurred; management views this as a class effect that typically resolves over time.
• BD Strategy: Open to licensing deals with pharma partners who have failed oral programs, existing programs lacking tolerability solutions, or new entrants.

Other Key Points:

• Safety Profile: No serious treatment-emergent adverse events (TEAEs) in Phase 1; all GI events were mild/moderate (Grade 1 in highest dose cohort).
• PK/PD: High bioavailability and prolonged exposure in humans matched non-clinical predictions, validating the once-daily dosing regimen.
• Compliance Checks: Drug compliance was monitored via pharmacokinetic trough levels (T0 values), which identified potential non-adherence in Cohort 4.
• Gastric Emptying: No gastric emptying studies were performed in this Phase 1; expected to be slowed similar to the class.